[Skip to Content]
[Skip to Content Landing]
Views 273
Citations 0
Comment & Response
June 2017

Negative Psychosis Prevention Trials

Author Affiliations
  • 1Department of Psychiatry, University of New Mexico, Albuquerque
JAMA Psychiatry. 2017;74(6):651-652. doi:10.1001/jamapsychiatry.2017.0187

To the Editor In 2010, Amminger et al1 showed a 29% reduction in transition to full-blown psychosis in ultrahigh risk patients who had received an ω-3 fatty acid supplement for 12 weeks, compared with placebo, when evaluated after 1 year. In JAMA Psychiatry, McGorry et al2 published a study that failed to show a benefit of ω-3 supplementation compared with placebo in transition to psychosis rates.

×